EP0810867A1 - Nouvelle utilisation de compositions contenant de la nacre - Google Patents
Nouvelle utilisation de compositions contenant de la nacreInfo
- Publication number
- EP0810867A1 EP0810867A1 EP96943169A EP96943169A EP0810867A1 EP 0810867 A1 EP0810867 A1 EP 0810867A1 EP 96943169 A EP96943169 A EP 96943169A EP 96943169 A EP96943169 A EP 96943169A EP 0810867 A1 EP0810867 A1 EP 0810867A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- pearl
- mother
- optionally
- aragonite
- skin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 24
- 239000000843 powder Substances 0.000 claims abstract description 22
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims abstract description 21
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 16
- 238000003786 synthesis reaction Methods 0.000 claims abstract description 16
- 239000002537 cosmetic Substances 0.000 claims abstract description 9
- 239000006143 cell culture medium Substances 0.000 claims abstract description 3
- 239000003814 drug Substances 0.000 claims abstract 2
- 210000003491 skin Anatomy 0.000 claims description 29
- 210000002510 keratinocyte Anatomy 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- 230000006872 improvement Effects 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 230000001681 protective effect Effects 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 4
- 231100000252 nontoxic Toxicity 0.000 claims description 2
- 230000003000 nontoxic effect Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000000969 carrier Substances 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 description 18
- 239000000126 substance Substances 0.000 description 13
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 230000000694 effects Effects 0.000 description 7
- 230000016571 aggressive behavior Effects 0.000 description 6
- 210000002615 epidermis Anatomy 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 102000000589 Interleukin-1 Human genes 0.000 description 5
- 108010002352 Interleukin-1 Proteins 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 210000000434 stratum corneum Anatomy 0.000 description 5
- 206010001488 Aggression Diseases 0.000 description 4
- 102000011782 Keratins Human genes 0.000 description 4
- 108010076876 Keratins Proteins 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 210000001787 dendrite Anatomy 0.000 description 2
- RXKJFZQQPQGTFL-UHFFFAOYSA-N dihydroxyacetone Chemical compound OCC(=O)CO RXKJFZQQPQGTFL-UHFFFAOYSA-N 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000002752 melanocyte Anatomy 0.000 description 2
- 230000003716 rejuvenation Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000008719 thickening Effects 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000237858 Gastropoda Species 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 241000237852 Mollusca Species 0.000 description 1
- 241000237536 Mytilus edulis Species 0.000 description 1
- 238000000184 acid digestion Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 210000000736 corneocyte Anatomy 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229940120503 dihydroxyacetone Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000008099 melanin synthesis Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 235000020638 mussel Nutrition 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 230000003711 photoprotective effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001012 protector Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- HOZOZZFCZRXYEK-HNHWXVNLSA-M scopolamine butylbromide Chemical compound [Br-].C1([C@@H](CO)C(=O)OC2C[C@@H]3[N+]([C@H](C2)[C@@H]2[C@H]3O2)(C)CCCC)=CC=CC=C1 HOZOZZFCZRXYEK-HNHWXVNLSA-M 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229920006268 silicone film Polymers 0.000 description 1
- 230000036560 skin regeneration Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000000433 stratum disjunctum Anatomy 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/60—Fish, e.g. seahorses; Fish eggs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/987—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of species other than mammals or birds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4741—Keratin; Cytokeratin
Definitions
- the invention relates to a new use of mother-of-pearl for medical and / or cosmetic purposes.
- the reference US-A-4,393,045 (EG HENDERSON et al.) Relates to components of mother-of-pearl having a curative effect, by application of a preparation obtained after contacting a fruit containing citric acid with the shell of a mollusc containing the pearly part. Only the organic part of the mother-of-pearl is preserved.
- the reference EP-A-0 393 267 (M. KATO et al.) Describes a bioactive substance obtained by heating the mother-of-pearl for several hours at very high temperature. This heating appears to activate a plant and animal growth agent.
- the reference WO-A-95 30426 (S. CAMPRASSE et al.) Relates to a product for skin regeneration and healing, obtained from a ground material of the pearly test and a lyophilisate from animal cells which are treated with enzymatic and thermal route.
- the reference DE-A-34 37 184 (E. IWAN et al.) Relates to an agent for treating burns based on a mixture of pulverized shells of mussels and snails. The shells are washed beforehand with water and dried. This mixture has an antibacterial action.
- Patent FR-A-2 715 568 (J. VIRASSAMY) claims the use of mother-of-pearl powder for bone reconstruction.
- mother of pearl has been known for a long time for its regenerative properties of bones.
- the Applicant has found that mother-of-pearl contains in its crystal structure substances capable of activating the cells of the animal and in particular of making it possible to repair the shell of conchifers when it is injured.
- Certain substances contained in the biomineral which is mother-of-pearl are of a protein nature and respond well to the antibodies directed against human and rat collagens, type I and III. There is therefore an analogy between the skin and the shell of conchifers.
- the Applicant has studied and verified that the mother-of-pearl contains original substances which could intervene in the processes of restructuring, stimulation, etc., of the skin.
- the Applicant has studied the consequences of the use of mother-of-pearl on other types of cells such as fibrobiasts, lymphocytes, keratinocytes and endothelial cells.
- the pearl powder added in the culture of keratinocytes unexpectedly causes an increased synthesis of cytokeratins.
- the structure present on the skin surface must be a substance naturally produced by epithelial cells, such as keratinocytes, which contributes to the physiological thickening of the epidermis.
- the solution chosen was to choose not to strip the skin to bring new cell structures to the surface, but to make keratinocytes produce newly formed substances, the cytokeratins, which normally generate these cells when they are young or active.
- the present invention more specifically consists in the use of a powder formed of mother-of-pearl and optionally of aragonite, in finely pulverulent form and mixed with suitable excipients, for the production of pharmaceutical and / or cosmetic compositions intended to improve the synthesis of new cytokeratins.
- the invention also consists in the use of a powder formed of mother-of-pearl and optionally of aragonite, in finely pulverulent form and mixed with suitable excipients, with a view to its application in cell culture media in order to improve synthesis. new cytokeratins.
- the very important synthesis of new cytokeratins ensures the improvement of the qualities and appearance of the skin, and in particular makes it possible to ensure the processes of restoration of the structure of the skin, to exert a protective role on the skin and to give it active resistance in aggressive outdoor conditions (sun, cold, prolonged exposure to water, etc.), to improve properties mechanical skin, giving it a youthful and dynamic appearance, thanks to a newly formed structure on the surface.
- the powder formed of mother-of-pearl and aragonite is constituted such that the mixture contains mother-of-pearl in a proportion ranging from 0.1% to 98% in the total mixture, and preferably in a proportion ranging from 5 to 20% in the total mixture.
- the tests described below were preferably carried out with a preparation consisting of 10% mother-of-pearl and 90% aragonite.
- the present invention also relates to pharmaceutical and / or cosmetic compositions ensuring the improvement of the qualities and appearance of the skin, characterized in that they consist of mother-of-pearl, optionally added with aragonite, in combination or in mixture with an inert, non-toxic, powdery excipient or diluent.
- mother-of-pearl makes it possible to develop a dermo-protective effect, it is in the synthesis of the constituents of the Stratum corneum that we find the most modifications. Since the stratum corneum is formed by the condensation of cytokeratins, the Applicant has directed its analyzes towards this material. The possible consequences are essentially in the quality of the response of cells to the stress of an aggression (synthesis of interleukin 1: IL-1). In addition, the skin is subjected to an important photoluminous activity to which it responds by the synthesis of a photoprotective element: melanin. There is therefore a decrease in the synthesis of melanin or a better distribution of the latter in keratinocytes.
- Cytokeratins are distinguished by their molecular weight and for most of them there is a specific antibody. In order to study the whole phenomenon, an antibody was used against all of the cytokeratins. Because of this, it is called anti-pan cytokeratins.
- a cell culture of keratinocytes obtained from surgical skin samples was therefore carried out.
- the skin is treated by enzymatic digestion and incubation in a specific medium (modified Mac Koy or of the KBM-Basai Medium Keratinocyte type): culture medium containing no serum.
- the “Western Blot” technique is an analytical technique based on the separation of proteins according to their molecular weight by electrophoresis followed by immunological detection. A second layer antibody grafted to an enzyme reveals the first antibody when contacted with a chromogenic substrate.
- pan cytokeratins the quantification of the substance to be assayed, here pan cytokeratins, is done by simple absorption spectrophotometry or by image analysis of the revelation plate. Under these conditions, it was found that the basic hypothesis was verified and that the nacre was capable of doubling the quantity of cytokeratins synthesized by the keratinocytes. The results are studied taking into account the total protein synthesis over several dilutions, because on the one hand the number of cells is not strictly constant, and on the other hand their activity is not necessarily coordinated.
- mother-of-pearl increases the synthesis of pan cytokeratins by a multiplicative factor of the order of 2.
- Figure 1 is a graphical representation of the evolution of the synthesis of pan cytokeratins as a function of the volume tested. There was shown the signal cytokeratin X 10 / ⁇ g total protein ratio for the control and for mother-of-pearl preparations.
- cytokeratins improves the mechanical properties of the skin, it is possible to consider a protective role for mother-of-pearl during attacks.
- Two types of response to aggression can be considered: responses to chemical or biological aggressions involving interleukin in first intention and responses involving melanin.
- FIG. 2 represents the results obtained during the culture of the cell line
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Birds (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Marine Sciences & Fisheries (AREA)
- Cosmetics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9515225A FR2742661B1 (fr) | 1995-12-21 | 1995-12-21 | Nouvelle utilisation de compositions contenant de la nacre |
| FR9515225 | 1995-12-21 | ||
| PCT/FR1996/002053 WO1997023231A1 (fr) | 1995-12-21 | 1996-12-20 | Nouvelle utilisation de compositions contenant de la nacre |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP0810867A1 true EP0810867A1 (fr) | 1997-12-10 |
Family
ID=9485773
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP96943169A Withdrawn EP0810867A1 (fr) | 1995-12-21 | 1996-12-20 | Nouvelle utilisation de compositions contenant de la nacre |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP0810867A1 (ja) |
| JP (1) | JPH11501055A (ja) |
| AP (1) | AP9701086A0 (ja) |
| BR (1) | BR9607043A (ja) |
| CA (1) | CA2214095A1 (ja) |
| FR (1) | FR2742661B1 (ja) |
| IL (1) | IL121576A0 (ja) |
| NO (1) | NO973826L (ja) |
| PL (1) | PL321870A1 (ja) |
| WO (1) | WO1997023231A1 (ja) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2777460A1 (fr) * | 1998-04-15 | 1999-10-22 | Fred Distribution Karon | Composition de gommage de l'epiderme et methode de gommage associee |
| FR2782641B1 (fr) * | 1998-08-27 | 2002-05-10 | Regent Genus Organisms Interna | Medicament homeopathique comprenant un ou plusieurs composants de la nacre |
| JP2003081750A (ja) * | 2001-09-14 | 2003-03-19 | Mikimoto Pharmaceut Co Ltd | 化粧品または食品 |
| DE10215342A1 (de) * | 2002-03-28 | 2003-10-23 | Coty Bv | Hautaufhellendes Kosmetikum |
| DE10239029A1 (de) * | 2002-08-21 | 2004-03-04 | Coty B.V. | Kosmetische und dermatologische Zubereitung mit Proteinen zur Hautaufhellung |
| FR2856303B1 (fr) * | 2003-06-20 | 2007-09-07 | Innovation Et De Rech Applique | Utilisation therapeutique de lipides extraits de nacre |
| FR2863163B1 (fr) * | 2003-12-04 | 2006-02-24 | Oreal | Composition, notamment cosmetique, comprenant des extraits de fougere et de nacre |
| FR2880277B1 (fr) * | 2005-01-04 | 2007-04-06 | Georges Camprasse | Preparations a usage orthopedique et dermatologique, destinees aux equides, bovides et autres animaux domestiques a base de biopolymeres marins, solubles et insolubles, et de biocritaux d'aragonite |
| JP2009209093A (ja) * | 2008-03-04 | 2009-09-17 | Shiseido Co Ltd | 皮膚バリアー機能回復促進剤及び皮膚外用剤 |
| FR2946885B1 (fr) * | 2009-06-17 | 2011-08-26 | Phagexel | Composition de nacre destinee a corriger des defauts de nidation chez les mammiferes. |
| JP5679402B2 (ja) * | 2010-02-08 | 2015-03-04 | 御木本製薬株式会社 | 皮膚角化促進剤 |
| JP2011195521A (ja) * | 2010-03-23 | 2011-10-06 | Mikimoto Pharmaceut Co Ltd | 皮膚角化促進剤 |
| FR3062302B1 (fr) * | 2017-02-01 | 2020-12-04 | Cosmoluxury | Nouvelle composition cosmetique comprenant de la nacre ou un extrait de nacre |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4393045A (en) * | 1981-10-29 | 1983-07-12 | Henderson Esther G | Cosmetic composition |
| DE3437184A1 (de) * | 1984-10-10 | 1986-04-17 | Eduard Iwan | Mittel zum behandeln von hautverbrennungen und ein verfahren zur herstellung dieses mittels |
| JPH01117833A (ja) * | 1987-10-29 | 1989-05-10 | Masatoshi Kato | 生物活性物質 |
| FR2715568B1 (fr) * | 1994-01-28 | 1996-04-12 | Joseph Virassamy | Utilisation de poudre de nacre pour prothèse et implants de prothèse conçus pour cela. |
| CN1071119C (zh) * | 1994-02-25 | 2001-09-19 | 上海益人生化技术开发有限公司 | 酶解珍珠液 |
| FR2719478B1 (fr) * | 1994-05-09 | 1996-07-26 | Serge Camprasse | Produit de régénération et de cicatrisation cutanée. Son procédé de fabrication ses applications. |
-
1995
- 1995-12-21 FR FR9515225A patent/FR2742661B1/fr not_active Expired - Fee Related
-
1996
- 1996-12-20 PL PL96321870A patent/PL321870A1/xx unknown
- 1996-12-20 AP APAP/P/1997/001086A patent/AP9701086A0/en unknown
- 1996-12-20 BR BR9607043A patent/BR9607043A/pt not_active Application Discontinuation
- 1996-12-20 WO PCT/FR1996/002053 patent/WO1997023231A1/fr not_active Application Discontinuation
- 1996-12-20 JP JP9523370A patent/JPH11501055A/ja active Pending
- 1996-12-20 EP EP96943169A patent/EP0810867A1/fr not_active Withdrawn
- 1996-12-20 CA CA002214095A patent/CA2214095A1/fr not_active Abandoned
- 1996-12-20 IL IL12157696A patent/IL121576A0/xx unknown
-
1997
- 1997-08-20 NO NO973826A patent/NO973826L/no unknown
Non-Patent Citations (1)
| Title |
|---|
| See references of WO9723231A1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| FR2742661A1 (fr) | 1997-06-27 |
| PL321870A1 (en) | 1997-12-22 |
| WO1997023231A1 (fr) | 1997-07-03 |
| NO973826L (no) | 1997-10-21 |
| CA2214095A1 (fr) | 1997-07-03 |
| IL121576A0 (en) | 1998-02-08 |
| BR9607043A (pt) | 1997-12-30 |
| FR2742661B1 (fr) | 1998-07-10 |
| NO973826D0 (no) | 1997-08-20 |
| AP9701086A0 (en) | 1997-10-31 |
| JPH11501055A (ja) | 1999-01-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1221957B1 (fr) | Procede de preparation d'une composition par extraction de nacre et son utilisation en cosmetique et dermatologie | |
| CA2395283C (fr) | Utilisation d'un extrait d'au moins un vegetal du genre vaccinium comme agent anti-glycation | |
| EP0810867A1 (fr) | Nouvelle utilisation de compositions contenant de la nacre | |
| EP1776082B1 (fr) | Utilisation d'un hydrolysat de proteines de cruciferes en tant qu'agent depigmentant dans ou pour une composition cosmetique et/ou pharmaceutique | |
| US20230139983A1 (en) | Method for obtaining collagen peptide from starfish, elastic liposome comprising starfish-derived collagen peptide, and cosmetic composition comprising same | |
| EP2953611B1 (fr) | Utilisation d'une composition comprenant un perséose d'avocat dans la protection des cellules souches épidermiques | |
| FR2791684A1 (fr) | Composition cosmetiques ou dermopharmaceutiques contenant le tripeptide n-n-biotinyl-gly-his-lys pour prevenir, reduire ou supprimer la chute des cheveux ainsi que pour favoriser leur repousse | |
| FR2540381A1 (fr) | Procede pour stimuler la croissance des cellules; composition cosmetique, pharmaceutique et composition complementaire pour milieu de culture cellulaire appliquant ce procede | |
| FR2925326A1 (fr) | Utilisation d'un hydrolysat de mais en tant que principe actif activateur de la synthese des aquaporines | |
| KR20090071998A (ko) | 초유를 함유하는 피부외용제 조성물 | |
| WO2009043991A2 (fr) | Utlisation d'un principe actif issu du lin dans une composition destinee a activer le cytochrome c | |
| EP3980124B1 (fr) | Extrait du tourteau des graines de moringa peregrina, son procédé d'obtention et son utilisation dans des compositions cosmétiques ou nutricosmétiques | |
| CA2908535A1 (fr) | Applications cosmetiques et pharmaceutiques de lactobacillus pentosus | |
| EP2986983A2 (fr) | Utilisation de biomarqueurs de la barrière pour l'évaluation de l'efficacité d'actifs | |
| EP1131048B1 (fr) | Extrait de tourteau de graines de noix | |
| WO2009010587A1 (fr) | Utilisation d'au moins un extrait de parties aériennes de l'epilobe et/ou de l'onagre pour la préparation d'une composition destinée à restaurer la fonction barrière des tissus kératinisés ou des muqueuses. | |
| JP5164681B2 (ja) | 口唇化粧料及び飴並びにチューイングガム | |
| FR2874502A1 (fr) | Nouvel extrait vegetal, son procede d'obtention et ses applications pharmaceutiques, nutraceutiques ou cosmetiques | |
| EP2496308B1 (fr) | Utilisation d'un hydrolysat peptidique de maïs en tant qu'agent actif stimulant la pousse du cheveu | |
| EP2150232A2 (fr) | Utlisation d'un principe actif issu de l'amarante (amaranthus) pour preparer une composition destinee a activer l'energie cellulaire et a proteger la peau des dommages oxydatifs | |
| FR2832926A1 (fr) | Composition cosmetique ou dermatologique comprenant un retinoide et/ou un carotenoide et l'acide acexamique | |
| CA3231786A1 (fr) | Peptides et compositions pharmaceutiques et cosmetiques les contenant | |
| CN115998770A (zh) | 拟鳞花软珊瑚提取物及其用途 | |
| FR3084261A1 (fr) | Compositions cosmetiques ou dermatologiques | |
| JP2020002034A (ja) | Ｖｅｇｆ産生促進剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI GB GR IE IT LI LU NL SE |
|
| RBV | Designated contracting states (corrected) |
Designated state(s): AT BE CH DE DK ES FI GB GR IE IT LI LU NL SE |
|
| RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: SERRAR, MOSTAFA Inventor name: MILET, CHRISTIAN Inventor name: LOPEZ, EVELYNE Inventor name: GUTIERREZ, GILLES |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 19980105 |